ClearBridge Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

ClearBridge Investments’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-135,496	Closed	-$972K	–	724
2025 Q3	$972K	Buy	135,496 +107,069	+377%	+$5.58M	﹤0.01%	656
2025 Q2	$1.34M	Sell	28,427 -4,185	-13%	-$170K	﹤0.01%	630
2025 Q1	$1.27M	Sell	32,612 -10,768	-25%	-$464K	﹤0.01%	625
2024 Q4	$2.35M	Buy	43,380 +9,106	+27%	+$465K	﹤0.01%	615
2024 Q3	$1.73M	Buy	34,274 +5,738	+20%	+$269K	﹤0.01%	625
2024 Q2	$1.25M	Sell	28,536 -15	-0.1%	-$635	﹤0.01%	659
2024 Q1	$1.43M	Buy	+28,551	New	+$1.55M	﹤0.01%	647

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ClearBridge Investments's MLTX Position: Q4 2025 in Review

ClearBridge Investments sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 135,496 shares — an estimated $972K sold.

ClearBridge Investments first reported a position in MLTX in Q1 2024 and held it in 7 quarters. The position peaked at $2.35M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

ClearBridge Investments reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
ClearBridge Investments sold 135,496 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $972K.
ClearBridge Investments first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 7 quarters.
ClearBridge Investments's MoonLake Immunotherapeutics position peaked at $2.35M in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on ClearBridge Investments's 13F filing for Q4 2025, filed 11 Feb 2026.